# Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

> **NCT04543279** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 3 (actual)

## Conditions studied

- Myelofibrosis
- Thrombocytopenia

## Interventions

- **DRUG:** Fostamatinib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04543279
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-03
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-30
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543279, "Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04543279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*